K. Goyal

发表

Comment on: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”

A. Greenspan, Antonio Pires, K. Goyal, 2018, Drugs.

Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

A. Gottlieb, L. Naldi, K. Papp, 2015, Journal of drugs in dermatology : JDD.

Considerations for the US health-system pharmacist in a world of biosimilars

K. Goyal, Andrea Zlatkus, Todd Bixby, 2020, Drugs in context.

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).

B. Strober, M. Lebwohl, L. Naldi, 2016, Journal of the American Academy of Dermatology.

Extension of ustekinumab maintenance dosing interval in moderate‐to‐severe psoriasis: results of a phase IIIb, randomized, double‐blinded, active‐controlled, multicentre study (PSTELLAR)

L. Ferris, E. Muñoz-Elías, A. Blauvelt, 2017, The British journal of dermatology.

Reversible posterior leukoencephalopathy syndrome in a patient treated with ustekinumab: case report and review of the literature.

P. Saltiel, S. Fakharzadeh, K. Goyal, 2011, Archives of Dermatology.

Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry

M. Lebwohl, R. Langley, D. Fiorentino, 2017, Journal of the American Academy of Dermatology.

Biological treatment for psoriasis and the risk of herpes zoster: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

M. Lebwohl, L. Naldi, A. Nikkels, 2019, The Journal of dermatological treatment.

A descriptive analysis of real-world treatment patterns of innovator (Remicade®) and biosimilar infliximab in an infliximab-naïve Turkish population

E. Mutlu, Lin Xie, Y. Yazici, 2018, Biologics : targets & therapy.

Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab

Lin Xie, Y. Yazici, K. Goyal, 2018, Biologics : targets & therapy.

Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)

B. Strober, A. Kimball, A. Menter, 2018, Journal of the American Academy of Dermatology.

THU0434 Serious Infections in Psoriasis Patients with Psoriatic Arthritis in The Psoriasis Longitudinal Assessment and Registry Study

A. Gottlieb, A. Menter, P. Mease, 2016 .

THU0450 All-Cause Mortality and Malignancies in Psoriasis Patients with Psoriatic Arthritis in The Psoriasis Longitudinal Assessment and Registry Study

A. Gottlieb, A. Menter, P. Mease, 2016 .

Development of the IL‐12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives – an update

M. Mascelli, Honghui Zhou, M. Plotnick, 2012, Annals of the New York Academy of Sciences.

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

M. Lebwohl, Y. You, C. Leonardi, 2015, JAMA dermatology.

Drug survival of biologic therapy in a large, disease‐based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

A. Menter, M. Gooderham, K. Papp, 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)*

A. Menter, W. Gulliver, C. Leonardi, 2014, The British journal of dermatology.

Mo1884 Prevalence of Inflammatory Bowel Disease Among Patients With Psoriasis and Incidence of Serious Infections in This Subset: Results From the PSOLAR Registry

M. Augustin, E. Loftus, G. Krueger, 2016 .

Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies.

A. Gottlieb, A. Menter, E. D. De Jong, 2014, Journal of drugs in dermatology : JDD.

WITHDRAWN: Experience with ustekinumab in patients with psoriasis enrolled in a large, multicenter, prospective, disease-based registry (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).

A. Gottlieb, L. Naldi, K. Papp, 2015, Journal of the American Academy of Dermatology.

Ensuring Product Quality, Consistency and Patient Supply over Time for a Large-Volume Biologic: Experience with Remicade®

Lawrence Doolittle, Richard Melsheimer, Melissa Calmann, 2018, BioDrugs.

Development of the IL‐12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives

M. Mascelli, Honghui Zhou, M. Plotnick, 2011, Annals of the New York Academy of Sciences.

Observations from our evaluation of bodyweight changes after initiation of a biologic therapy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

A. Kimball, A. Armstrong, A. Menter, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Non-Melanoma Skin Cancer Risk Among Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

G. Krueger, S. Kalia, R. Langley, 2019, Journal of drugs in dermatology : JDD.

Correlation of psoriasis activity with socioeconomic status: cross‐sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

A. Kimball, K. Gordon, M. Augustin, 2018, The British journal of dermatology.

B. Strober, M. Lebwohl, L. Naldi, 2016 .

Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)

A. Kimball, A. Menter, C. Leonardi, 2014, The British journal of dermatology.